GB2448535A - New use for cannabinoid-containing plant extracts - Google Patents

New use for cannabinoid-containing plant extracts Download PDF

Info

Publication number
GB2448535A
GB2448535A GB0707610A GB0707610A GB2448535A GB 2448535 A GB2448535 A GB 2448535A GB 0707610 A GB0707610 A GB 0707610A GB 0707610 A GB0707610 A GB 0707610A GB 2448535 A GB2448535 A GB 2448535A
Authority
GB
United Kingdom
Prior art keywords
cannabinoid
containing plant
channel
plant extract
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0707610A
Other languages
English (en)
Other versions
GB0707610D0 (en
Inventor
Vincenzo Di Marzo
Luciano De Petrocellis
Aniello Schiano Moriello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Operations UK Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Priority to GB0707610A priority Critical patent/GB2448535A/en
Publication of GB0707610D0 publication Critical patent/GB0707610D0/en
Priority to ES08737019T priority patent/ES2717839T3/es
Priority to US12/596,500 priority patent/US20100249223A1/en
Priority to EP08737019.3A priority patent/EP2146731B1/en
Priority to PCT/GB2008/001359 priority patent/WO2008129258A1/en
Priority to CN200880016574A priority patent/CN101678059A/zh
Priority to JP2010503587A priority patent/JP5775300B2/ja
Priority to CA002684562A priority patent/CA2684562A1/en
Publication of GB2448535A publication Critical patent/GB2448535A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
GB0707610A 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts Withdrawn GB2448535A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB0707610A GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts
ES08737019T ES2717839T3 (es) 2007-04-19 2008-04-17 Extractos de plantas que contienen cannabinoides para el tratamiento del cáncer de próstata
US12/596,500 US20100249223A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts
EP08737019.3A EP2146731B1 (en) 2007-04-19 2008-04-17 Cannabinoid-containing plant extracts for the treatment of prostate cancer
PCT/GB2008/001359 WO2008129258A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts
CN200880016574A CN101678059A (zh) 2007-04-19 2008-04-17 含大麻素的植物提取物的新用途
JP2010503587A JP5775300B2 (ja) 2007-04-19 2008-04-17 カンナビノイド含有植物抽出物の新規な用途
CA002684562A CA2684562A1 (en) 2007-04-19 2008-04-17 New use for cannabinoid-containing plant extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0707610A GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts

Publications (2)

Publication Number Publication Date
GB0707610D0 GB0707610D0 (en) 2007-05-30
GB2448535A true GB2448535A (en) 2008-10-22

Family

ID=38135105

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0707610A Withdrawn GB2448535A (en) 2007-04-19 2007-04-19 New use for cannabinoid-containing plant extracts

Country Status (8)

Country Link
US (1) US20100249223A1 (enExample)
EP (1) EP2146731B1 (enExample)
JP (1) JP5775300B2 (enExample)
CN (1) CN101678059A (enExample)
CA (1) CA2684562A1 (enExample)
ES (1) ES2717839T3 (enExample)
GB (1) GB2448535A (enExample)
WO (1) WO2008129258A1 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147439A1 (en) * 2008-06-04 2009-12-10 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations
GB2478595A (en) * 2010-03-12 2011-09-14 Gw Pharma Ltd Phytocannabinoids for use in the treatment of cancer
GB2491118A (en) * 2011-05-20 2012-11-28 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US10758514B2 (en) 2013-06-19 2020-09-01 Gw Pharma Limited Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
US12121499B2 (en) 2011-09-29 2024-10-22 Gw Pharma Ltd. Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US12275914B2 (en) 2013-09-18 2025-04-15 Scientific Holdigs, LLC Electronic inhalation device
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
KR101063352B1 (ko) 2008-11-28 2011-09-07 고려대학교 산학협력단 Ｔｒｐａ１ 활성 억제 약물 및 이의 활용
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
JP6061448B2 (ja) * 2011-03-10 2017-01-18 株式会社マンダム 被験物質の評価方法
KR20120111125A (ko) * 2011-03-31 2012-10-10 주식회사한국전통의학연구소 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US10307446B2 (en) 2014-03-21 2019-06-04 St&T International, Inc. Cannabis extraction method and compositions
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CN105477635A (zh) * 2014-09-15 2016-04-13 中国人民解放军第二军医大学 一种治疗持续性慢性疼痛的靶点和药物
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CA3135893C (en) 2014-10-21 2023-11-14 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2016295728B2 (en) * 2015-07-22 2020-07-23 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
JP2018529736A (ja) * 2015-09-30 2018-10-11 ホーグ、ジョージ、エドワードＨＯＡＧ， Ｇｅｏｒｇｅ， Ｅｄｗａｒｄ 局所鎮痛性疼痛緩和製剤、その製造及び使用方法
EP3380096A4 (en) 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
JP7454332B2 (ja) * 2016-06-15 2024-03-22 オーハイ エナジェティクス ピービーシー 酸化ストレスを低減するための方法および組成物
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CN109963595B (zh) * 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN110621312A (zh) 2017-03-05 2019-12-27 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 用于治疗癌症的组合物和方法
CN110913839A (zh) * 2017-05-22 2020-03-24 Gbs全球生物制药公司 靶向trpv1的含月桂烯和大麻素的组合物
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
JP7231617B2 (ja) 2017-08-31 2023-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN109939014A (zh) * 2017-12-20 2019-06-28 汉义生物科技（北京）有限公司 一种含有大麻素的口气清新剂
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
BR112020020850A2 (pt) 2018-04-09 2021-01-19 Ellevet Sciences Extrato de cânhamo para tratamento da dor em animais
WO2019222459A1 (en) * 2018-05-18 2019-11-21 Diverse Biotech, Inc. Cannabinoid preparations and therapeutic uses
EP3796903A1 (en) * 2018-05-22 2021-03-31 GBS Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation
CA3104795A1 (en) * 2018-06-28 2020-01-02 Canopy Growth Corporation Compositions and methods for agonizing the cb2 receptor
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020230071A1 (en) * 2019-05-16 2020-11-19 Buzzelet Development And Technologies Ltd. Local anesthetic comprising a trp channel modulator
MX2022003189A (es) 2019-09-16 2022-06-08 Vapor Cartridge Tech Llc Sistema de administración de fármacos con sustratos apilables.
CN112569220B (zh) * 2019-09-30 2023-03-07 云南汉盟制药有限公司 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4037663A1 (en) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP2023527629A (ja) * 2020-03-20 2023-06-30 ザ・クイーンズ・メディカル・センター カンナビノイド組成物
AU2021258909A1 (en) * 2020-04-24 2022-12-08 Zyus Life Sciences Inc. Cannabichromene formulation for pain management
KR102433007B1 (ko) * 2020-07-28 2022-08-16 동의대학교 산학협력단 산골취 추출물을 포함하는 신경병증성 통증 예방 및 개선용 조성물
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
EP4568702A1 (en) 2022-08-12 2025-06-18 Jazz Pharmaceuticals Research UK Limited Oral solid dosage forms comprising cannabinoids
CN119912407B (zh) * 2023-10-31 2026-03-10 北京红惠新医药科技有限公司 大麻二酚环氧化物的制备方法及应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
JPH0426622A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 制癌剤
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999052524A1 (en) * 1998-04-14 1999-10-21 The Mathilda & Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
WO2002069993A1 (de) * 2001-03-06 2002-09-12 Forschungsinstitut Hiscia Verein Für Krebsforschung Cannabis extrakten pharmazeutische zusammensetzung
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2394894A (en) * 2002-11-04 2004-05-12 G W Pharma Ltd New use for pharmaceutical composition
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2007053526A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Compositions and methods for identifying modulators of trpv2
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) * 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
AU2002231970B2 (en) * 2001-02-14 2007-08-16 CNX Therapeutics Limited Mucoadhesive pharmaceutical formulations
WO2003087158A2 (en) * 2002-04-16 2003-10-23 Bayer Healthcare Ag Regulation of human transient receptor potential channel
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) * 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
JPH0426622A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 制癌剤
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999052524A1 (en) * 1998-04-14 1999-10-21 The Mathilda & Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
WO2002069993A1 (de) * 2001-03-06 2002-09-12 Forschungsinstitut Hiscia Verein Für Krebsforschung Cannabis extrakten pharmazeutische zusammensetzung
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2394894A (en) * 2002-11-04 2004-05-12 G W Pharma Ltd New use for pharmaceutical composition
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2007053526A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Compositions and methods for identifying modulators of trpv2
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Antiinflammatory properties of cannabichromene", P.W. Wirth et al, Life Sciences, (1980), 26(23), 1991-1995 *
"Antitumour activity of plantcannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma", A. Ligresti et al, Journal of Pharmacology and Experimental Therapeutics, (2006), 318(3), 1375-1387 *
WPI Abstract Accession No 1992-084357/11 & JP 4026622 A *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260043B2 (en) 2007-05-17 2022-03-01 Sutter Bay Hospitals Methods and compositions for treating cancer
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
US11344527B2 (en) 2007-05-17 2022-05-31 Sutter Bay Hospitals Methods and compositions for treating cancer
WO2009147439A1 (en) * 2008-06-04 2009-12-10 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations
US8632825B2 (en) 2008-06-04 2014-01-21 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations
EP2544682B1 (en) 2010-03-12 2016-02-10 GW Pharma Limited Phytocannabinoids in the treatment of cancer
GB2478595A (en) * 2010-03-12 2011-09-14 Gw Pharma Ltd Phytocannabinoids for use in the treatment of cancer
WO2011110866A1 (en) * 2010-03-12 2011-09-15 Gw Pharma Limited Phytocannabinoids in the treatment of cancer
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8790719B2 (en) 2010-03-12 2014-07-29 Gw Pharma Limited Phytocannabinoids in the treatment of cancer
US9675654B2 (en) 2010-03-12 2017-06-13 Gw Pharma Limited Phytocannabinoids in the treatment of cancer
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2524689A (en) * 2011-05-20 2015-09-30 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9895342B2 (en) 2011-05-20 2018-02-20 Gw Pharma Limited Cannabinoids for use in the treatment of neuropathic pain
GB2491118A (en) * 2011-05-20 2012-11-28 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2013038157A1 (en) 2011-09-12 2013-03-21 Gw Pharma Limited Phytocannabinoids for use in the treatment of cancer
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
US12121499B2 (en) 2011-09-29 2024-10-22 Gw Pharma Ltd. Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10758514B2 (en) 2013-06-19 2020-09-01 Gw Pharma Limited Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
US12275914B2 (en) 2013-09-18 2025-04-15 Scientific Holdigs, LLC Electronic inhalation device
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Also Published As

Publication number Publication date
JP2010524912A (ja) 2010-07-22
CN101678059A (zh) 2010-03-24
EP2146731A1 (en) 2010-01-27
EP2146731B1 (en) 2019-01-16
US20100249223A1 (en) 2010-09-30
ES2717839T3 (es) 2019-06-25
WO2008129258A1 (en) 2008-10-30
GB0707610D0 (en) 2007-05-30
JP5775300B2 (ja) 2015-09-09
CA2684562A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
EP2146731B1 (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
Giacoppo et al. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
US20230285303A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4725478A2 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
Zhou et al. Allicin protects rat cortical neurons against mechanical trauma injury by regulating nitric oxide synthase pathways
Papanas et al. Emerging drugs for diabetic peripheral neuropathy and neuropathic pain
JP2009541479A (ja) 神経因性疼痛の治療用カンナビノイド
WO2019008393A1 (en) COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL NEUROPATHY
JP2012140437A (ja) 肥満、肥満に関連する障害、および他の障害の治療／管理におけるプレグナン配糖体の使用
KR20150120479A (ko) 니트라이트의 약제학적 제형 및 이의 용도
Saleh et al. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors
Gholamzadeh et al. Intravenous injection of apelin-13 improves sensory-motor balance deficits caused by cerebral ischemic reperfusion injury in male wistar rats via restoration of nitric oxide
Khalid et al. Osteoarthritis: From complications to cure
HK1139877A (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
HK1139877B (en) Cannabinoid-containing plant extracts for the treatment of prostate cancer
KR102445087B1 (ko) 통증 관리용 제형
EP3167881A1 (en) Locally administered ethamsylate as a medicament
US11395813B1 (en) Cannabinoids based pharmaceutical composition
CN113117090A (zh) 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
US20190015381A1 (en) Cannabinoid Formulation and Products
Chauhan et al. The potential of cannabis in pain management
KR100523452B1 (ko) 한약재 향기성분을 함유하는 불면 및 경련의 치료 및예방용 약제학적 조성물
Ross The analgesic effects of cannabis

Legal Events

Date Code Title Description
R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20120124

Free format text: EXTENSION ALLOWED

Effective date: 20120329

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20120529

Free format text: EXTENSION APPLICATION

Effective date: 20120320

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20120524

Free format text: EXTENSION ALLOWED

Effective date: 20120730

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)